Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …

Nucleic acid is the main material for storing, copying, and transmitting genetic information.
Gene sequencing is of great significance in DNA damage research, gene therapy, mutation …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Salicylic acid (SA) is an important phytohormone mediating both local and systemic defense
responses in plants. Despite over half a century of research, how plants biosynthesize SA …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …